ReviewReproductive sciences (Thousand Oaks, Calif.)2026
Endometriosis and the Hallmarks of Cancer.
Review in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis (EMS) is a non-cancerous invasive condition where tissue resembling the lining of the uterus is found outside of the uterine cavity. Endometriotic lesions have been found in nearly every organ of the body. This review highlights examples of EMS exhibiting all eight established hallmarks of cancer: hyperproliferation (e.g. through estrogen signalling), evasion of growth suppression (e.g. through progesterone resistance), immunosurveillance evasion (e.g. through reduction of natural killer cell cytotoxicity), enabling replicative immortality (e.g. through increased telomere length), invasion (e.g. through epithelial-to-mesenchymal transition), induction of angiogenesis (e.g. through upregulation of hypoxia-inducible factors), resistance to apoptosis (e.g. through increased expression of survivin), and deregulation of cellular metabolism (e.g. through increased production of lactate). Therefore, despite being considered a non-cancerous, benign condition, EMS is highly cancer-like in its behaviours to promote invasion and ectopic survival. The presence of all hallmarks of cancer amongst endometriotic behaviours highlights that to expand understanding of endometriotic metastasis, as well as potential modes for management of EMS, it may be possible to leverage the larger knowledge base associated with cancer.
Indexed as
Identifiers
41436710What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.